



Increasing the quality of life in NSCLC patients by Obdivo and Taxoter with hyperthermia

Sophie Badgaradze

Medical Center "BAURET", Georgia

Abstract:

Topicality: Treatment of oncological patients and getting clinical remission is an unforlunate topic even for the 21st century, despite the correctly selected therapy, which gives minimal risks of complications because of the chemo sensitive tests, there are important problems connected with the quality of life of patients and naturally we ask questions to ourselves: How could we manage to increase the quality of life in oncological patients on the 3rd and 4th levels and decrease the number of the side effects that accompany Ch/therapy and R/therapy procedures.

Aim: The aim of the study was the patient with a 55-year diagnostic: NSCLC-Thigh bone MTS, 3rd stage; R therapy and 4 Courses CH /therapy; ECOG-2 .Clinical remission was not achieved; Symptoms of progression of the hip fracture were strengthened, and the institution was addressed with the aforementioned history.

Methods and Materials: For the patient was selected CH-courses with hyperthermia and target therapy, we use Docetaxel 80 mg / m2 and obdivo recommended to strengthen the course effectiveness, weaken toxicity and to improve the quality of life recommended for the treatment CH/therapy + target therapy with hyperthermia and hypoglycemic; For this procedure, a hyperthermic camera was installed, where the procedure is carried out at 43-48 degrees Celsius, and we have a sugar content of 25-30000 per one 40-45 min / l in the bloodstream

Results: Only 2 courses were conducted with the patient with a CH/therapy and target therapy with hyperthermia. So, we managed to get medical results through high-level hyperthermic chemotherapy, patient's clinical remission and this was without any side effects. Increasing the quality of life. We recommend giving a hyperthermic chemotherapy and target therapy in oncological patients at 3rd and 4th stage, which is a firm guarantee of increasing their quality of life.

Biography

- 1992 – 1996 – Institute of Critical Care Medicine - Faculty of Medicine, Tbilisi Medical State University
- 2010 Gr. Robakidze Georgian - American University – PhD, Tbilisi.
- 2012 PhD student of the Natural Sciences of Tbilisi State University. Scientific topic: The modern method of treatment of uterine tumors by bleomycin, low-pulmonary drug. Tbilisi.

[International Conference on Oncology and Cancer research](#) | Paris, France | March 05-04, 2020

Citation: Sophie Badgaradze, Increasing the quality of life in NSCLC patients by Obdivo and Taxoter with hyperthermia *Oncology 2020* [International Conference on Oncology and Cancer research] Paris, France, June 24-25, 2020